comparemela.com

Latest Breaking News On - ஆசிய நிதி க்கு புற்றுநோய் ஆராய்ச்சி - Page 2 : comparemela.com

Winner of the AIM-HI Accelerator Fund s Inaugural Women s Venture Competition Announced

Winner of the AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition Announced Share Article ROCKVILLE, Md. (PRWEB) February 22, 2021 Privo Technologies and its chief executive officer, Manijeh Goldberg, Ph.D., have been selected as the winner of the AIM-HI Accelerator Fund’s inaugural Women’s Venture Competition, a first of its kind program for female entrepreneurs starting oncology companies. Privo Technologies has developed a nano-engineered platform for redesigning the mechanism of action of potent cancer medicines. The company was selected from among 47 female-led oncology start-ups following rigorous review and evaluation by three blue ribbon committees. As a result, Privo Technologies has received investment totaling $900,000 $300,000 from AIM-HI and matching investments from two supporters of the Women’s Venture Competition.

Winner of the AIM-HI Accelerator Fund s Inaugural Women s Venture Competition Announced

Winner of the AIM-HI Accelerator Fund s Inaugural Women s Venture Competition Announced
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma Brain Cancer

 at Henry Ford Health System . “Through global collaboration, GBM AGILE is making it possible for some of the world’s foremost experts in glioblastoma research and treatment to collaborate and advance the pace at which scientific and clinical breakthroughs can be achieved.” After opening at Henry Ford Cancer Institute, the two new interventions –   VAL-083   from Kintara Therapeutics, Inc.  and   paxalisib   from Kazia Therapeutics Limited– will subsequently open at more than 35 trial sites across the United States, with additional global sites in Canada, Europe and China to follow.   VAL-083   is being evaluated in all three glioblastoma patient subtypes: newly-diagnosed methylated MGMT; newly-diagnosed unmethylated MGMT; and recurrent.  

Henry Ford Cancer Institute first-in-world to activate new treatments in GBM AGILE Trial

 E-Mail IMAGE: Tom Mikkelsen, M.D., principal investigator for GBM AGILE at Henry Ford Cancer Institute, and medical director of the Precision Medicine Program and Clinical Trials Office at Henry Ford Health System.. view more  Credit: Henry Ford Health System DETROIT (Feb. 3, 2021) - Henry Ford Cancer Institute is the first site in the world to activate two new treatments for glioblastoma (GBM), the deadliest form of brain cancer, as part of a patient-centered adaptive platform trial known as GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). Led by Global Coalition for Adaptive Research (GCAR), GBM AGILE tests multiple therapies for patients with newly-diagnosed and recurrent GBM.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.